Sagimet Biosciences Inc. (SGMT)
NASDAQ: SGMT · Real-Time Price · USD
8.75
+0.63 (7.76%)
At close: Apr 28, 2026, 4:00 PM EDT
8.79
+0.04 (0.46%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Sagimet Biosciences Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Sagimet Biosciences stock have an average target of 26.38, with a low estimate of 8.00 and a high estimate of 35. The average target predicts an increase of 201.49% from the current stock price of 8.75.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 11, 2026.
Analyst Ratings
The average analyst rating for Sagimet Biosciences stock from 8 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 6 | 5 |
| Buy | 3 | 3 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 9 | 9 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +231.43% | Mar 11, 2026 |
| Guggenheim | Guggenheim | Strong Buy Initiates $27 | Strong Buy | Initiates | $27 | +208.57% | Feb 3, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $29 | Strong Buy | Reiterates | $29 | +231.43% | Feb 3, 2026 |
| Barclays | Barclays | Hold Initiates $8 | Hold | Initiates | $8 | -8.57% | Jan 28, 2026 |
| Citizens | Citizens | Buy Maintains $33 → $35 | Buy | Maintains | $33 → $35 | +300.00% | Nov 14, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
4.86M
EPS This Year
-1.60
from -1.58
EPS Next Year
-1.88
from -1.60
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | n/a | 38.7M | ||||||
| Avg | n/a | 4.9M | ||||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.17 | -0.97 | ||||||
| Avg | -1.60 | -1.88 | ||||||
| Low | -2.21 | -3.11 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.